You are here

P&T® Journal contents for February 2003

Features

Cover Story
The authors explain the benefits of ACE-inhibitors in controlling the progression of renal disease.
Tomoko Terajima, MS Pharm, Shin-ichi Yamagata, MS Pharm, Nobunori Satoh, PhD, and Shiro Ueda, MD
Physician Perspective
A family practitioner discovers some of the lessons to be learned from treating a terminally ill patient.
Thomas Marzili, MD
Pharmaceutical-Approval Update
The author reviews ezetimibe for lowering blood lipid levels, atomoxetine for attention-deficit hyperactivity disorder, and injectable teriparatide for osteoporosis.
Marvin M. Goldenberg, PhD
Letter to the Editor
Drug companies can satisfy their customers by responding to their increasing demands for information.
Paul Spiegelman
CE/CME
The authors discuss a new topical therapeutic agent for the treatment of genital warts and other skin conditions.
David J. Najarian, BS, and Joseph C. English III, MD

Departments

Editorial
Editor-in-Chief Dr. David Nash reports on California’s Integrated Healthcare Association.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger describes the potential pitfalls of pharmacy computer-generated medication administration records.
Matthew Grissinger
Drug News
The latest information about approvals, indication changes, industry updates, and news from the FDA.
Prescription Washington
Stephen Barlas discusses the FDA’s latest proposal on generic drugs.
Stephen Barlas
Drug Forecast
Drs. Kleyman and Sisca review eplerenone for the treatment of hypertension.
Jennie Kleyman, PharmD, and Thomas S. Sisca, PharmD
P&T Snapshot
Both ACE-inhibitors and beta blockers are commonly prescribed for patients with hypertension, but the numbers are changing.